News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 673 results
December 2021
-
Media ReleaseNovartis Cosentyx® receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritisNew approvals are based on JUNIPERA trial data showing Cosentyx® (secukinumab) demonstrated reduced flare risk versus placebo and improvement in disease activity observed over two years across both…
-
Media ReleaseFDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year
-
Media ReleaseFDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a yearWith two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction(1) Leqvio provides effective and sustained…
-
Media ReleaseNovartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021
-
Media ReleaseNovartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as foundation for various investigational CAR-T therapies Early data from first-in-human dose-…
-
Media ReleaseNovartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up
-
Media ReleaseNovartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-upComplete and overall response rates and durability of response were well maintained across majority of high-risk subgroups with a significant unmet need1 Median follow-up of approximately 17…
-
Media ReleaseNovartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i
-
Media ReleaseNovartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6iNew data underscore efficacy of Piqray, even in those patients with a short treatment duration on prior CDK4/6i or with ESR1 mutations, biomarkers of endocrine resistance[1-5] Recent guideline…
-
Media ReleaseNew Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer
-
Media ReleaseNew Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancerData from the MONALEESA Phase III program provide further evidence of the unique profile of Kisqali, the CDK4/6 inhibitor with the longest reported median overall survival (OS) in HR+/HER2-…
Pagination
- ‹ Previous page
- 1
- …
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- …
- 57
- › Next page